Literature DB >> 19590968

Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis.

Kalyan C Nannuru1, Mitsuru Futakuchi, Anguraj Sadanandam, Thomas J Wilson, Michelle L Varney, Kathleen J Myers, Xiaodong Li, Eric G Marcusson, Rakesh K Singh.   

Abstract

The bone microenvironment plays a critical role in tumor-induced osteolysis and osteolytic metastasis through tumor-bone (TB)-interaction. Receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) is one of the critical signaling molecules involved in osteolysis and bone metastasis. However, the regulation and functional significance of RANKL at the TB-interface in tumor-induced osteolysis remains unclear. In this report, we examined the role of tumor-stromal interaction in the regulation of RANKL expression and its functional significance in tumor-induced osteolysis. Using a novel mammary tumor model, we identified that RANKL expression was upregulated at the TB-interface as compared to the tumor alone area. We demonstrate increased generation of sRANKL at the TB-interface, which is associated with tumor-induced osteolysis. The ratio of RANKL to osteoprotegrin (OPG), a decoy receptor for RANKL, at the TB-interface was also increased. Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface. Together, these results demonstrate that upregulation of RANKL expression and sRANKL generation at the TB-interface potentiates tumor-induced osteolysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590968     DOI: 10.1007/s10585-009-9279-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  51 in total

Review 1.  Antisense oligonucleotides as a tool for gene functionalization and target validation.

Authors:  C F Bennett; L M Cowsert
Journal:  Biochim Biophys Acta       Date:  1999-12-10

2.  Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase.

Authors:  J Schlöndorff; L Lum; C P Blobel
Journal:  J Biol Chem       Date:  2001-01-30       Impact factor: 5.157

Review 3.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

4.  Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

Authors:  Luis Costa; Laurence M Demers; A Gouveia-Oliveira; J Schaller; Eduardo B Costa; Miguel C de Moura; Allan Lipton
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 5.  Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

Authors:  Julie M Blair; Hong Zhou; Markus J Seibel; Colin R Dunstan
Journal:  Nat Clin Pract Oncol       Date:  2006-01

6.  Kinetics of metastatic breast cancer cell trafficking in bone.

Authors:  Pushkar A Phadke; Robyn R Mercer; John F Harms; Yujiang Jia; Andra R Frost; Jennifer L Jewell; Karen M Bussard; Shakira Nelson; Cynthia Moore; John C Kappes; Carol V Gay; Andrea M Mastro; Danny R Welch
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

Review 7.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

8.  Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.

Authors:  Klaus Jung; Carsten Stephan; Axel Semjonow; Michael Lein; Dietmar Schnorr; Stefan A Loening
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

9.  Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.

Authors:  Jian Zhang; Jinlu Dai; Zhi Yao; Yi Lu; William Dougall; Evan T Keller
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

10.  Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.

Authors:  Colm Morrissey; Paul L Kostenuik; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  BMC Cancer       Date:  2007-08-03       Impact factor: 4.430

View more
  7 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.

Authors:  Sonia de Assis; Anni Warri; Carlos Benitez; William Helferich; Leena Hilakivi-Clarke
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

3.  Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.

Authors:  Kalyan C Nannuru; Mitsuru Futakuchi; Michelle L Varney; Thomas M Vincent; Eric G Marcusson; Rakesh K Singh
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

4.  The RhoGEF Net1 is required for normal mammary gland development.

Authors:  Yan Zuo; Rebecca Berdeaux; Jeffrey A Frost
Journal:  Mol Endocrinol       Date:  2014-12

Review 5.  Bone metastasis: the importance of the neighbourhood.

Authors:  Peter I Croucher; Michelle M McDonald; T John Martin
Journal:  Nat Rev Cancer       Date:  2016-05-25       Impact factor: 60.716

6.  A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.

Authors:  Anguraj Sadanandam; Mitsuru Futakuchi; Costas A Lyssiotis; William J Gibb; Rakesh K Singh
Journal:  BMC Cancer       Date:  2011-07-20       Impact factor: 4.430

Review 7.  Targeting RANKL in metastasis.

Authors:  William C Dougall; Ingunn Holen; Eva González Suárez
Journal:  Bonekey Rep       Date:  2014-04-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.